Old Web
English
Sign In
Acemap
>
authorDetail
>
Amy C. Stoll
Amy C. Stoll
Gemcitabine
Medicine
Phases of clinical research
Pathology
FOLFIRINOX
4
Papers
25
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
2017
Journal of Clinical Oncology
Gayle S. Jameson
Erkut Borazanci
Hani M. Babiker
Elizabeth Poplin
Anna A. Niewiarowska
Michael S. Gordon
Michael T. Barrett
Karen Ansaldo
Leticia Lebron
Amy C. Stoll
Adam Rosenthal
Lynn R. Shemanski
Ronald L. Korn
Ramesh K. Ramanathan
Daniel D. Von Hoff
Show All
Source
Cite
Save
Citations (14)
Phase II study of nab-paclitaxel/gemcitabine (NabP-Gem) alternating with FOLFIRI as 1st line therapy ( Rx) in patients (pts) with metastatic pancreatic cancer (mPC).
2015
Journal of Clinical Oncology
Vincent J. Picozzi
Joseph Leach
Timothy S. Larson
Carol Y. Nishikubo
Stephen P. Anthony
Bruce S. Lin
Vanessa Bolejack
Amy C. Stoll
Daniel D. Von Hoff
Ramesh K. Ramanathan
Show All
Source
Cite
Save
Citations (0)
Phase II study of induction therapy with gemcitabine and nab-paclitaxel followed by consolidation with mFOLFIRINOX in patients with metastatic pancreatic cancer.
2013
Journal of Clinical Oncology
Ramesh K. Ramanathan
Peter D. Lee
John E. Seng
Stephen P. Anthony
Peter Rosen
Raul R. Mena
Vincent J. Picozzi
Jasgit C. Sachdev
Timothy S. Larson
Ronald L. Korn
Gayle S. Jameson
Amy C. Stoll
Daniel D. Von Hoff
Joseph W. Leach
Show All
Source
Cite
Save
Citations (9)
1